Achieve Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Additional Information (Detail)

Related Party Transactions - Additional Information (Detail)								5 Months Ended	8 Months Ended	9 Months Ended	12 Months Ended		16 Months Ended	20 Months Ended
	Jul. 24, 2017 USD ($) $ / shares shares	Jul. 20, 2017 shares	Jul. 19, 2017 shares	Jul. 18, 2017 USD ($) $ / shares shares	Mar. 07, 2017 USD ($)	Sep. 30, 2015 USD ($) $ / shares shares	May 18, 2015 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2015 USD ($) shares	Sep. 30, 2016 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2016 USD ($) NotesPayable $ / shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2016 USD ($) $ / shares	Jul. 31, 2017 USD ($)
Related Party Transaction [Line Items]
Accounts payable, related parties												$ 829,000	$ 829,000	$ 829,000
Debt conversion, converted instrument, amount									$ 2,000,000
Common stock, par value \| $ / shares								$ 0.001			$ 0.001	$ 0.001	$ 0.001	$ 0.001
Accrued salaries												$ 1,028,000	$ 1,028,000	$ 1,028,000
Common Stock
Related Party Transaction [Line Items]
Debt conversion, converted instrument, shares issued \| shares									4,500
Ricanto, Ltd [Member]
Related Party Transaction [Line Items]
Consulting fees incurred, related parties										$ 100,000	$ 0
Related party consulting agreement, date of termination											Aug. 01, 2017
Accounts payable, related parties				$ 600,000				$ 0			$ 0	600,000	600,000	600,000
Shares issued to related party for services \| shares				475
Shares issued to related party, par value \| $ / shares				$ 0.01
Ricanto, Ltd [Member] \| OncoGenex Pharmaceuticals, Inc [Member] \| Common Stock
Related Party Transaction [Line Items]
Conversion of each outstanding share of Achieve common stock , shares converted \| shares				359.3053
Number of shares post-conversion \| shares				170,670
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts payable, related parties								0			0
Notes payable, related parties												$ 200,000	200,000	200,000
Number of notes payable \| NotesPayable												2
Notes payable, rate of interest												3.50%
Notes payable repayment period												1 year
Outstanding principal, included in shareholder loans												$ 200,000	200,000	200,000
Accrued interest owed to related party								0			0	3,000	3,000	3,000
Salary paid														0
Chief Executive Officer [Member] \| Accrued Compensation [Member]
Related Party Transaction [Line Items]
Salary paid								400,000
Accrued salaries												700,000	700,000	700,000
Accrued salaries, common stock shares issued \| shares			238
Percentage of common stock issued in settlement of accrued salaries			50.00%
Percentage of cash payment in settlement of accrued salaries			50.00%
Chief Executive Officer [Member] \| Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Shares issued to related party, par value \| $ / shares	$ 0.01
Debt conversion, converted instrument, amount	$ 200,000
Debt conversion, converted instrument, shares issued \| shares	146
Chief Executive Officer [Member] \| OncoGenex Pharmaceuticals, Inc [Member] \| Common Stock
Related Party Transaction [Line Items]
Conversion of each outstanding share of Achieve common stock , shares converted \| shares	359.3014		359.3025
Number of shares post-conversion \| shares	52,458		85,514
Lender
Related Party Transaction [Line Items]
Accounts payable, related parties								0			0	700,000	700,000	700,000
Notes payable, related parties					$ 20,000
Notes payable, rate of interest					3.50%
Notes payable repayment period					1 year
Accrued interest owed to related party								0			0	35,000	35,000	35,000
Debt conversion, converted instrument, amount	$ 800,000
Debt conversion, converted instrument, shares issued \| shares	586
Common stock, par value \| $ / shares	$ 0.01
Lender \| Convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Notes payable, related parties							$ 2,700,000
Notes payable, rate of interest							3.50%
Debt conversion, converted instrument, amount						$ 2,000,000
Debt conversion, converted instrument, shares issued \| shares						4,500
Common stock, par value \| $ / shares						$ 0.01
Lender \| OncoGenex Pharmaceuticals, Inc [Member] \| Common Stock
Related Party Transaction [Line Items]
Conversion of each outstanding share of Achieve common stock , shares converted \| shares	359.3052
Number of shares post-conversion \| shares	1,827,426
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts payable, related parties								0			0
Accrued interest owed to related party								0			0
Salary paid													0
Chief Financial Officer [Member] \| Accrued Compensation [Member]
Related Party Transaction [Line Items]
Salary paid								200,000
Accrued salaries												$ 300,000	$ 300,000	$ 300,000
Accrued salaries, common stock shares issued \| shares		127
Percentage of common stock issued in settlement of accrued salaries		50.00%
Percentage of cash payment in settlement of accrued salaries		50.00%
Chief Financial Officer [Member] \| OncoGenex Pharmaceuticals, Inc [Member] \| Common Stock
Related Party Transaction [Line Items]
Conversion of each outstanding share of Achieve common stock , shares converted \| shares		359.2992
Number of shares post-conversion \| shares		45,631
Michelle Griffin [Member] \| OncoGenex Pharmaceuticals, Inc [Member]
Related Party Transaction [Line Items]
Termination fee payable															$ 600,000
Michelle Griffin [Member] \| OncoGenex Pharmaceuticals, Inc [Member] \| Accrued Liabilities Other [Member]
Related Party Transaction [Line Items]
Accounts payable, related parties								$ 0			$ 0